Poster

EQS-News: Galimedix Therapeutics presents new scientific data showing promising neuroprotective effects of GAL-201 for the treatment of Alzheimer’s disease at AD/PD™ 2024

Retrieved on: 
수요일, 3월 13, 2024

These new findings strongly support previous studies where GAL-201 was characterized as a promising development candidate for the treatment of AD ( Russ et.

Key Points: 
  • These new findings strongly support previous studies where GAL-201 was characterized as a promising development candidate for the treatment of AD ( Russ et.
  • The data was presented this week at the International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders ( AD/PD™ 2024: advances in science and therapy ).
  • “The positive results presented at AD/PD™ 2024 demonstrate how treatment with GAL-201 has a potential neuroprotective effect and may also improve cognitive function.
  • Furthermore, they validate that toxic Aβ oligomers and protofibrils are a major underlying cause of this devastating disease, and not the deposited forms of Aβ.

EQS-News: Galimedix Therapeutics announces new pre-clinical data with GAL-201 in an Alzheimer's disease transgenic model to be presented at AD/PD™ 2024 Conference

Retrieved on: 
수요일, 3월 13, 2024

The issuer is solely responsible for the content of this announcement.

Key Points: 
  • The issuer is solely responsible for the content of this announcement.
  • Kensington, MD, USA, February 28, 2024 –Galimedix Therapeutics, Inc. (“Galimedix”), a Phase 2 clinical-stage biotechnology company developing novel oral and topical neuroprotective therapies with the potential to revolutionize the treatment of serious eye and brain diseases, announced the presentation of new in vitro and in vivo data with orally available small molecule GAL-201, an amyloid beta aggregation modulator, in a transgenic model of Alzheimer's disease (AD) at the International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders (AD/PD™ 2024).
  • The conference will take place March 5 - 9, 2024 in Lisbon, Portugal.
  • The following poster will be presented:
    Title: The amyloid beta aggregation modulator GAL-201 is under development for oral AD treatment: Cognitive improvement in a transgenic AD model
    The poster will include data showing the beneficial effects of GAL-201 in an established transgenic mouse model of AD, both in vitro as well as in behavioral experiments, showing its promise as a treatment of AD.

EQS-News: Immunic to Participate in Investor and Scientific Conferences in March

Retrieved on: 
수요일, 3월 13, 2024

NEW YORK, March 7, 2024 – Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following investor and scientific conferences in March:

Key Points: 
  • NEW YORK, March 7, 2024 – Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following investor and scientific conferences in March:
    March 11-13: Leerink Partners Global Biopharma Conference.
  • Daniel Vitt, Ph.D., Chief Executive Officer and President of Immunic, and Jessica Breu, Vice President Investor Relations and Communications, will participate in one-on-one investor meetings at this conference in Miami, FL.
  • Two abstracts have been accepted for poster presentations at this conference in Munich, Germany.
  • The poster presentations will be accessible on the “Events and Presentations” section of Immunic’s website at: https://ir.imux.com/events-and-presentations .

Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market - A Race Worth Winning

Retrieved on: 
수요일, 3월 6, 2024

Research Nester says , "The global pancreatic cancer market size is slated to expand at ~18% CAGR between 2024 and 2036.

Key Points: 
  • Research Nester says , "The global pancreatic cancer market size is slated to expand at ~18% CAGR between 2024 and 2036.
  • The American Cancer Society's estimates for pancreatic cancer in the United States for 2024 are: "About 66,440 people (34,530 men and 31,910 women) will be diagnosed with pancreatic cancer.
  • Pancreatic cancer accounts for about 3% of all cancers in the US and about 7% of all cancer deaths."
  • Biotech/oncology stocks targeting the growing global pancreatic cancer market have made headlines with recent developments and breakthroughs in treatments.

Galimedix Therapeutics presents new scientific data showing promising neuroprotective effects of GAL-201 for the treatment of Alzheimer’s disease at AD/PD™ 2024

Retrieved on: 
금요일, 3월 8, 2024

These new findings strongly support previous studies where GAL-201 was characterized as a promising development candidate for the treatment of AD ( Russ et.

Key Points: 
  • These new findings strongly support previous studies where GAL-201 was characterized as a promising development candidate for the treatment of AD ( Russ et.
  • The data was presented this week at the International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders ( AD/PD™ 2024: advances in science and therapy ).
  • “The positive results presented at AD/PD™ 2024 demonstrate how treatment with GAL-201 has a potential neuroprotective effect and may also improve cognitive function.
  • Furthermore, they validate that toxic Aβ oligomers and protofibrils are a major underlying cause of this devastating disease, and not the deposited forms of Aβ.

Provectus Biopharmaceuticals Announces Acceptance of Cancer Immunotherapy PV-10 Abstract for HNSCC at AACR 2024 Annual Meeting

Retrieved on: 
목요일, 3월 7, 2024

The abstract, which was accepted for a poster presentation, is titled “ PV 10 induces endoplasmic reticulum stress and autophagy, triggering immunogenic cell death and anti-tumor immunity in head and neck squamous cell carcinoma ” (Abstract #6742, Topic Track: Immunology, Session: Vaccines, Antigens, and Antigen Presentation 2).

Key Points: 
  • The abstract, which was accepted for a poster presentation, is titled “ PV 10 induces endoplasmic reticulum stress and autophagy, triggering immunogenic cell death and anti-tumor immunity in head and neck squamous cell carcinoma ” (Abstract #6742, Topic Track: Immunology, Session: Vaccines, Antigens, and Antigen Presentation 2).
  • According to Moffitt’s abstract, “…in vitro findings reveal that PV-10 induces cytotoxicity in both mEER and MTE-RAS cells.
  • Notably, PV-10 promotes a significant increase in [reactive oxygen species], leading to an elevation in late apoptotic cells.
  • At the molecular level, a remarkable activation of endoplasmic reticulum (ER) stress, pro-apoptotic protein, and autophagy markers were observed.

Telomir Pharmaceuticals Presents Promising Pre-Clinical Data For Its Lead Development Product at Singapore Conference

Retrieved on: 
목요일, 3월 7, 2024

The data presented was garnered from pre-clinical studies that Telomir previously disclosed it was undertaking.

Key Points: 
  • The data presented was garnered from pre-clinical studies that Telomir previously disclosed it was undertaking.
  • The data presented further demonstrated how Telomir-1 increases telomere length and its potential to successfully affect age-related inflammatory conditions.
  • The collaboration is expected to help accelerate the development of Telomir-1, improve its safety profile, and significantly reduce the research and development costs of Telomir’s drug development program.
  • To be added to the Telomir Pharmaceuticals email distribution list, please email [email protected] with TELO in the subject line.

IO Biotech Announces Acceptance of Abstract to be Presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Retrieved on: 
수요일, 3월 6, 2024

NEW YORK, March 06, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win® platform, today announced that an abstract has been accepted for presentation at the American Association for Cancer Research Annual Meeting 2024 (AACR 2024), taking place April 5-10, 2024 in San Diego, CA.

Key Points: 
  • NEW YORK, March 06, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win® platform, today announced that an abstract has been accepted for presentation at the American Association for Cancer Research Annual Meeting 2024 (AACR 2024), taking place April 5-10, 2024 in San Diego, CA.
  • The poster will include nonclinical data related to IO Biotech’s lead therapeutic cancer vaccine candidate, IO102-IO103, currently being evaluated in a pivotal Phase 3 study.
  • “We are excited with our new nonclinical data clearly demonstrating how the dual antigen vaccine IO102-IO103 differentially contribute to the anti-tumor effect: while IO102 treatment results in the reduction of the immune suppression in the TME, IO103 appears to impact by enhancement of T effector function,” said Mai-Britt Zocca, Ph.D., President and CEO of IO Biotech.
  • “These findings further support the potential that co-administration of the dual antigen vaccine IO102-IO103 can benefit patients due to its impact on two separate immune resistance pathways, IDO1 and PD-L1, respectively.”

Enterome Announces Upcoming Presentation on OncoMimics™ Approach to Cancer Immunotherapy at the AACR Annual Meeting 2024

Retrieved on: 
수요일, 3월 6, 2024

The poster will be presented by Dr. Vincent Panneton, Postdoctoral Associate in Pharmacology at the Ludwig Collaborative Laboratory led by Dr. Taha Merghoub and Dr. Jedd Wolchok at Weill Cornell Medicine.

Key Points: 
  • The poster will be presented by Dr. Vincent Panneton, Postdoctoral Associate in Pharmacology at the Ludwig Collaborative Laboratory led by Dr. Taha Merghoub and Dr. Jedd Wolchok at Weill Cornell Medicine.
  • “We are pleased to announce the presentation of these promising preclinical data which provide novel insights into the design of OncoMimics™ peptides for both neoantigens and tumor-associated antigens.
  • These results serve as an early validation of our approach to novel cancer immunotherapies,” said Laurent Chêne, Head of Drug Discovery at Enterome.
  • The abstract will be published in an online supplement to Cancer Research, the official journal of the American Association for Cancer Research, on March 22nd, and the poster will be available on Enterome’s website after the AACR Meeting.

Biomea Fusion Presents Patient Cohorts in COVALENT-111 Displaying a Durable Placebo-Adjusted Mean Reduction of up to 1.4% in HbA1c While Off Therapy at Week-26, after BMF-219’s 28-Day Treatment Cycle, Supporting Improved Pancreatic Function

Retrieved on: 
수요일, 3월 6, 2024

REDWOOD CITY, Calif., March 06, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing oral covalent small molecules to treat and improve the lives of patients with metabolic diseases and genetically defined cancers, today announced three poster presentations presenting long-term 26 week follow-up data from patients treated with BMF-219, enrolled in the escalation portion of the ongoing Phase II clinical study (COVALENT-111), at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) taking place in Florence, Italy from March 6-9, 2024. This clinical data from all dosing cohorts initiated to date as of February 12, 2024 from the Escalation Phase of COVALENT-111 will be featured during a Poster Discussion Presentation and two Poster Viewing Presentations at ATTD. Biomea will showcase the following three e-poster presentations:

Key Points: 
  • Please find a link here to our website where the poster presentations and discussion will be available.
  • A higher proportion of patients treated with 200mg QD achieved a clinically significant reduction in HbA1c compared to 100mg QD dosing.
  • A durable glycemic response (≥1.0% HbA1C reduction) was seen in 20% and 36% of patients in once daily 100 mg and 200 mg cohorts, respectively.
  • A PK study further assessing the optimal use of BMF-219 to ensure minimal variability of exposure is currently under way.